ACADIA Pharmaceuticals Inc. Stock News

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF has commenced an investigation into Acadia Healthcare

In a report released today, Jay Olson from Oppenheimer assigned a Hold rating to Prothena (PRTA). The company's shares closed last Thursday at $11.50.

In a report released today, Jay Olson from Oppenheimer assigned a Hold rating to Prothena ( PRTA – Research Report ). The company’s shares closed last Thursday at $11.50. According to TipRanks.com

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) President Srdjan R. Stankovic sold 54,019 shares of the stock in a transaction dated Wednesday, April 22nd. The stock was sold at an average price of $50.02,

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) President Srdjan R. Stankovic sold 100,000 shares of the business’s stock in a transaction dated Monday, April 20th. The shares were sold at an average pric

The company's shares closed last Wednesday at $298.01. According to TipRanks.com, Olson 's ranking currently consits of no stars on a 0-5 ranking scale,

The company’s shares closed last Wednesday at $298.01. According to TipRanks.com, Olson ‘s ranking currently consits of no stars on

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Biohaven Pharmaceutical Holding Co (BHVN) and Cara

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Biohaven Pharmaceutical Holding Co ( BHVN – Research Report ) and Cara Therapeutics ( CARA – Resear

In a report released today, Alan Carr from Needham assigned a Buy rating to Cara Therapeutics (CARA), with a price target of $35.00. The company's shares

In a report released today, Alan Carr from Needham assigned a Buy rating to Cara Therapeutics (CARA – Research Report),

Needham analyst Alan Carr assigned a Buy rating to SCYNEXIS (SCYX) today and set a price target of $5.00. The company's shares closed last Tuesday at

Needham analyst Alan Carr assigned a Buy rating to SCYNEXIS (SCYX – Research Report) today and set a price target

Allred Capital Management LLC bought a new position in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) during the 1st quarter, HoldingsChannel reports. The institutional investor bought 2,000 shar

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) – Research analysts at Jefferies Financial Group issued their Q1 2020 earnings per share (EPS) estimates for shares of ACADIA Pharmaceuticals in a report is